Best Life Sciences Platforms and Tools Companies in Boston, United States
The 75 best Life Sciences Platforms and Tools companies in Boston, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: CELLINK.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Boston
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | CELLINK 🦄 Developer of 3D bioprinters and bioinks for research purposes | $389M | 63 mo ago | Public | 65 65 → 71 (+9%) | — | 146 patents Flexible multilayer printed circuit interconnects and terminal‑free connectors for battery packs | — |
| 2 | Dewpoint Therapeutics Developer of small molecule based therapeutics 53Funding top 17%Moat top 31%Talent top 38%News top 41% All 7 signals ▾Fundingtop 17% Moattop 31% Talenttop 38% Newstop 41% Markettop 45% Globalbottom 45% Techbottom 32% Funding: Raised $287M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 53/100 | $287M | 9 mo ago | Series D | 147 | Richard Young Co-Founder | — | 1 job opening |
| 3 | Emulate Developer of in vitro models for drug development 78Funding top 15%Patents top 25%Moat top 26%Innovation top 34% All 10 signals ▾Fundingtop 15% Patentstop 25% Moattop 26% Innovationtop 34% Techtop 34% Growthtop 40% Markettop 45% AItop 45% Globalbottom 49% Newsbottom 22% Funding: Raised $225M across 10 rounds · 10 rounds over 12 yrs (0.8/yr) Patents: 479 patents matched (strict assignee match) · 170 filings since 2022 vs 309 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $225M | 9 mo ago | Series E | 103 103 → 71 (-31%) | — | 479 patents Patents concentrated in chemistry & materials | 1 job opening |
| 4 | Microbia Developer of fine specialty chemicals | $224M | 231 mo ago | Acquired | — | Brian Cali Founder | 226 patents Microbial fermentation of therapeutic peptides and carotenoid production for GI drugs and food additives | — |
| 5 | SQZBiotech Developer of cell therapies to treat multiple diseases | $168M | 51 mo ago | Acquired | 117 | — | — | — |
| 6 | Life Biosciences Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases 53Funding top 16%Growth top 28%Moat top 31%News top 43% All 7 signals ▾Fundingtop 16% Growthtop 28% Moattop 31% Newstop 43% Techtop 49% Globalbottom 39% Marketbottom 33% Funding: Raised $150M across 9 rounds · 9 rounds over 8 yrs (1.1/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $150M | 2 mo ago | Series D | 14 14 → 27 (+93%) | — | — | — |
| 7 | 908 Devices Manufacturer of detection device for chemical analysis using mass spectrometry | $68M | 85 mo ago | Public | 93 93 → 210 (+126%) | Kevin Knopp CEO & Co-founder | 43 patents Microfluidic sample preparation and compact mass spectrometry for rapid bio‑analysis | 1 launch |
| 8 | Spear Bio Developer of ultrasensitive immunoassays and proteomics platforms for detecting protein biomarkers | $49M | 23 mo ago | Series A | 21 | Feng Xuan Co-Founder & CEO | — | 3 launchs |
| 9 | BICO Provider of technologies, products, and services for life sciences research purposes | $49M | 41 mo ago | Public | 955 955 → 897 (-6%) | Erik Gatenholm Co-Founder | — | 1 award |
| 10 | Enlight Biosciences Fostering health innovation through partnerships and technology development | $39M | 215 mo ago | Series B | — | David Steinberg Founder & ex-CEO | — | — |
| 11 | Nabla Provider of synthetic biology platform to identify functional proteins | $37M | 25 mo ago | Series A | 10 | Frances Anastassacos Co-Founder | — | — |
| 12 | Sample6 Food safety laboratories and consulting group providing testing and training | $32M | 107 mo ago | Acquired | — | Tim Lu Co-Founder | 24 patents Phage-based biosensor technologies for rapid bacterial detection and environmental monitoring. | — |
| 13 | Seahorse Bioscience Analytical instruments, lab supplies, and services for scientific research and diagnostics | $29M | 158 mo ago | Acquired | 200 | — | — | — |
| 14 | Arisaph Biopharmaceutical company focused on developing therapies for cardiometabolic diseases and cancer | $26M | 129 mo ago | Deadpooled | — | Christopher Kiritsy CEO & President | — | — |
| 15 | Apogee Intradermal drug delivery system using nanotechnology and MEMS | $23M | 177 mo ago | Funding Raised | — | Herbert Stein Chairman & CEO | 54 patents Patents concentrated in health & consumer products | — |
| 16 | CytoTronics Developer of cell-based assays for drug discovery | $23M | 27 mo ago | Series A | 12 12 → 8 (-33%) | Vince Wu Co-founder & CTO | 7 patents Semiconductor sensor platforms for high‑throughput multi‑well assay measurements. | — |
| 17 | Ginkgo Provider of autonomous laboratory systems for biological engineering and experimentation | $20M | 16 mo ago | Funding Raised | — | Austin Che Co-Founder | — | 1 launch · 2 awards |
| 18 | Aldatu Biosciences Innovative PCR diagnostics for infectious diseases, advancing global health emergency response | $18M | 45 mo ago | Funding Raised | 11 | — | — | — |
| 19 | NanoView Biosciences Provider of a nanotechnology based molecular diagnostic platform | $16M | 51 mo ago | Acqui-Hired | 24 | — | — | — |
| 20 | Thrive Bioscience Developer of smart devices for life science cell culture | $15M | 105 mo ago | Series A | 35 | Thomas Farb Co-Founder & COO | 162 patents Automated imaging, analysis, and IoT-controlled systems for cell culture monitoring and management | — |
| 21 | Parallel Fluidics Provider of microfluidic chips for research labs | $13M | 19 mo ago | Seed | 7 | Joshua G Co-Founder & CEO | 6 patents Microfluidic device fabrication and modular platform integration with laser-welded components and embedded valves. | — |
| 22 | Ark Biotech Manufacturer of bioreactors for producing cultivated meat | $11M | 25 mo ago | Series A | 22 | Yossi Quint Founder & CEO | — | — |
| 23 | Adeptrix Developer of bead-assisted mass spectroscopy technology for proteomics | $10M | 13 mo ago | Series A | 7 | — | 29 patents Multiplexed bead-based immunoassay platforms for high-throughput protein/biomarker analysis | — |
| 24 | Gel4Med Bioinspired medical solutions company developing advanced biomaterials for unmet clinical needs | $10M | 14 mo ago | Funding Raised | 4 | — | 40 patents Peptide-based self‑assembling hydrogels for regenerative medicine and targeted drug/cell delivery | 1 partnership |
| 25 | FLUID Provider of microfluidic technology for microbial profiling and diagnostics | $10M | 58 mo ago | Series A | 5 | Monika Weber Founder & CEO | — | — |
| 26 | BioTransplant Supplies tested tissues, allographs and implantable tissue products | $10M | 299 mo ago | Deadpooled | — | Jacque Ojadidi President | 18 patents Therapeutic anti‑CD2a antibodies for T‑cell activation inhibition in immunomodulation | — |
| 27 | LabMinds Automating buffer and sample preparation for quality control and digitized labs | $10M | 55 mo ago | Series C | 14 | — | 5 patents Automated liquid handling and dispensing systems for laboratory and biotech applications. | — |
| 28 | Spectra Analysis Provider of infrared spectroscopic instruments for molecular analysis | $9M | 158 mo ago | Acquired | 6 | Bill Carson Co-Founder | 12 patents Fluid handling and analytical instrumentation for suspensions and liquid sample analysis | — |
| 29 | Alivio Therapeutics Online Spaceman Slot game provider with a focus on Pragmatic Play | $7M | 69 mo ago | Funding Raised | 5 | Jeffrey Karp Co-Founder | — | — |
| 30 | PhagePro Developing phage treatments to combat antibiotic resistance and promote health equity | $5M | 18 mo ago | Funding Raised | 5 | Minmin Yen Co-Founder & CEO | — | — |
| 31 | Safi Bio Developer of developing cell therapies from hematopoietic progenitor cells | $5M | 21 mo ago | Seed | 7 | — | — | — |
| 32 | BrickBio Provider of targeted protein for research and therapeutic applications | $5M | 79 mo ago | Series A | 8 | Abhishek Chatterjee Co-Founder | 26 patents Site-specific incorporation of noncanonical amino acids into therapeutic proteins and antibodies | — |
| 33 | Entrega Technology for oral delivery of complex payloads | $5M | 102 mo ago | Series A | — | Daphne Zohar Founder & CEO | 33 patents Ionically chargeable hydrogel oral dosage forms for enhanced drug delivery | — |
| 34 | FreMon Scientific Innovating blood, plasma, and tissue processing for safe, efficient use | $4M | 86 mo ago | Seed | 9 | Frederick Thacher Co-Founder & CEO | — | — |
| 35 | Outpost Bio Developer of artificial intelligence to analyze microbial ecosystems for medicine | $4M | 3 mo ago | Seed | — | Alex Merwin Co-Founder & COO | — | 1 award |
| 36 | Advanced Proteome Therapeutics Technology platform to develop targeted treatment of cancers | $3M | 72 mo ago | Public | 5 | Allen Krantz President/CEO | — | — |
| 37 | Glycosyn Biotechnology firm enhancing health through human milk science and product development | $3M | 193 mo ago | Funding Raised | 6 | — | 146 patents Patents concentrated in chemistry & materials | — |
| 38 | Curadel Research company focused on NIR-based imaging technologies for biomedical applications | $2M | 36 mo ago | Seed | 9 | John Frangioni Founder & CEO | 33 patents Advanced micro‑CMOS optical and fluorescence tomography systems for medical imaging | — |
| 39 | AbVitro Provides immune sequencing technology to identify novel therapeutic targets and antibodies to cancer… | $2M | 156 mo ago | Acquired | 17 | Jeffrey Ostrove CEO | 128 patents Patents concentrated in chemistry & materials | — |
| 40 | Biological Lattice Industries Provider of 3D bioprinting solutions for tissue repair and regeneration | $2M | 20 mo ago | Seed | — | Filippos Tourlomousis Founder & CEO | — | — |
| 41 | EnEvolv Engineers microorganisms to produce chemicals, enzymes and small molecules for variety of industries. | $2M | 114 mo ago | Acquired | 607 | — | 30 patents Molecular and cell‑free biosensor platforms for detecting specific analytes and engineering genomes | — |
| 42 | Molecular Loop Developer of technology for targeted DNA sequencing | $2M | 52 mo ago | Seed | 12 | Greg Porreca Founder and CEO | 17 patents Genomic sequencing and structural variant detection using multiplex nucleic acid methods | — |
| 43 | IQ Proteomics Advanced proteomics services for comprehensive proteome characterization, from discovery to targeted analysis | $1M | 117 mo ago | Funding Raised | — | Brian Erickson Co-Founder & CEO | 4 patents Isobaric labeling reagents for quantitative proteomics mass‑spectrometry analysis | — |
| 44 | Almega.com Provider of laboratory equipment, chemicals, pilot plant design, and setup | $1M | 214 mo ago | Funding Raised | — | Thomas Kurien CEO | — | — |
| 45 | Transcera Bio Developer of biologic therapeutics for chronic diseases | $1M | 34 mo ago | Funding Raised | 6 | Wayne Lencer Co-Founder & MD | — | — |
| 46 | Flaskworks Manufacturer of immunotherapeutics for research purpose | $750K | 81 mo ago | Acqui-Hired | 4 | Shashi Murthy Founder | 107 patents Automated cell culture bioreactor systems for scalable biological production | — |
| 47 | IROA Technologies Mass spectrometry-based technologies for metabolomics | $700K | 153 mo ago | Series A | 4 | — | 17 patents Isotopic labeling methods for enhanced mass‑spectrometry metabolomics analysis | — |
| 48 | Commonwealth Informatics Data analytics and pharmacovigilance service provider | $678K | 141 mo ago | Acquired | 62 | — | — | — |
| 49 | MelliCell Developer of regenerative therapy for diabetes mellitus | $571K | 25 mo ago | Funding Raised | 8 | — | 6 patents Patents concentrated in chemistry & materials | 1 award |
| 50 | Biomembretics Developer of biomimetic microfluidic membranes for artificial organs | $294K | 21 mo ago | Funding Raised | — | Todd Astor Founder | — | — |
Top 12 Life Sciences Platforms and Tools companies in Boston
#1
Series D · Boston, Massachusetts · founded 2017 · 14 employees$150.2Mraised▾
Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases. The company is focused on targeting the biology of aging, which is the biggest risk factor for most chronic diseases. They are developing a novel partial epigenetic reprogramming platform that targets a key underlying mechanism of aging to prevent and reverse age-related diseases with significant unmet need to extend healthy human lifespan. This approach holds the promise of treating many of the most debilitating and chronic diseases. The platform builds on innovative science from world-leading researchers to partially reprogram the epigenome of aged and injured cells to restore cellular function to a younger state. This is a B2B model.
- Apr 2026Series D$80M
- Nov 2025Series C$31M
- Jan 2022Series C$82M
- Jun 2020Series B$18.2M
#2
Series E · Boston, Massachusetts · founded 2013 · 103 employees$225Mraised▾
Developer of in vitro models for drug development. The company has culture modules, organ-chips, and analytical software applications. The proprietary Organ-Chip models including the liver, intestine, kidney, and others contain tiny hollow channels lined with tens of thousands of living human cells and tissues are designed to predict human response.
- Sep 2025Grant (prize money)$493K
- Sep 2021Series E$82M
- Mar 2020Conventional Debt$19.3M
- Aug 2019Series C$28M
#3
Series D · Boston, Massachusetts · founded 2018 · 147 employees$287.1Mraised▾
Dewpoint Therapeutics is involved in development of small molecules based therapeutics. The company offers condensate biology to create dynamic, liquid compartments in cells for the treatment of neurodegeneration, cancer, and other diseases.
- Sep 2025Series D$59.1M
- Feb 2022Series C$150M
- Sep 2020Series B$77.1M
- Jan 2019Series A$60M
#4
Seed · Boston, Massachusetts · founded 2025$3.5Mraised▾
Developer of artificial intelligence to analyze microbial ecosystems for medicine. It builds a closed-loop engine pairing wet lab science with machine learning. This creates foundational models and datasets to advance open science. It enables a new generation of predictive medicine through microbial interactions. The company seeks collaborators with pre/post-intervention datasets of the microbiome.
- Mar 2026Seed$3.5M
#5
Series A · Boston, Massachusetts · founded 2010 · 7 employees$10.5Mraised▾
Developer of bead-assisted mass spectroscopy technology for proteomics. The company has developed a tool called BAMS (bead-assisted mass spectroscopy), which can be used to directly monitor key proteins and sites to advance drug discovery research and disease biology. It has applications in the production and analysis of microarrays.
- May 2025Grant (prize money)$2.5M
- Jul 2024Grant (prize money)$295.2K
- Sep 2022Grant (prize money)$2.5M
- Jul 2022Grant (prize money)$1.3M
#6
Funding Raised · Boston, Massachusetts · founded 2009$19.5Mraised▾
Provider of autonomous laboratory systems for biological engineering and experimentation. The company offers tools that automate scientific benchwork, enabling scientists to focus on data analysis and experimental design. It provides both complete autonomous labs and access to a cloud-based laboratory environment. The company supports research and development projects with experiment design and data analysis services.
- Feb 2025Grant (prize money)$3.2M
- Jan 2025Grant (prize money)$3.2M
- Jul 2010Grant (prize money)$13.1M
#7
Funding Raised · Boston, Massachusetts · founded 2015 · 4 employees$10.1Mraised▾
Bioinspired medical solutions company developing advanced biomaterials for unmet clinical needs. This is a commercial-stage company focused on shaping the future of medicine by harnessing the power of smart materials to address significant medical challenges. Utilizing bioinspiration and materials engineering, the company has developed a Smart Materials Platform for creating therapeutics and devices. Their lead asset targets wound care and surgical reconstruction. Committed to enhancing health outcomes and access for all patients, they develop novel biomaterials. The proprietary Smart Materials Platform is an innovative bioengineering approach for addressing a wide range of clinical needs. They collaborate and innovate around novel treatments. The company focuses on research and development to create advanced medical solutions.
- Apr 2025Grant (prize money)$1.2M
- Sep 2023Grant (prize money)$2.6M
- Aug 2020Grant (prize money)$300K
- Jul 2020Grant (prize money)$409.7K
#8
Series A · Boston, Massachusetts · founded 2021 · 21 employees$49Mraised▾
Developer of ultrasensitive immunoassays and proteomics platforms for detecting protein biomarkers. It offers TNAB-sure SARS-CoV-2 neutralizing antibody test kits for detecting antibodies in small samples. It also, offer a reagent-based platform for ultrasensitive protein detection in small sample volumes, with applications in research and diagnostics.
- Jul 2024Series A$45M
- Nov 2023Seed—
- Oct 2022Seed$2.4M
- Oct 2021Seed$1.6M
#9
Seed · Boston, Massachusetts · founded 2020 · 7 employees$12.6Mraised▾
Provider of microfluidic chips for research labs. The company uses embossing and micromachining 3D technology and develops microfluidic chips for custom cartridges.
- Nov 2024Seed$7M
- Dec 2022Seed$3.8M
- Nov 2021Angel$1.8M
- Sep 2021Seed$1.4M
#10
Funding Raised · Boston, Massachusetts · founded 2016 · 5 employees$5.2Mraised▾
Developing phage treatments to combat antibiotic resistance and promote health equity. This organization is dedicated to developing phage treatments for global health disparities and antibiotic resistance. They harness the power of phages, natural hunters of bacteria, to tackle prolific diseases as an alternative to antibiotics. The company brings together experts in public policy, industry, and commercialization with community leaders to drive innovation in underserved communities. Their lead program focuses on Cholera, reflecting their commitment to addressing critical health challenges. This is a biotech company focused on social impact, offering innovative solutions to combat antibiotic resistance and promote health equity through phage therapy.
- Dec 2024Grant (prize money)$1M
- Jul 2024Grant (prize money)$173.3K
- Jan 2021Grant (prize money)$383.2K
- Dec 2018Grant (prize money)$3.6M
#11
Series A · Boston, Massachusetts · founded 2020 · 10 employees$37Mraised▾
Provider of synthetic biology platform to identify functional proteins
- May 2024Series A$26M
- Dec 2021Seed$11M
- Apr 2021Grant (prize money)$256K
#12
CELLINK 🦄Public · Boston, Massachusetts · founded 2016 · 65 employees$388.8Mraised▾
Developer of 3D bioprinters and bioinks for research purposes. It designs and develops 3D bioprinters for cell culture, tissue engineering, and drug development applications. The company also offers single-cell dispensers, liquid handlers, bioreactors, live-cell analyzers, omics, NGS reagents, bio-inks, biomaterials, and other consumables.
- Mar 2021Post IPO$323.1M
- Jan 2021Grant (prize money)$762.6K
- Sep 2020Grant (prize money)$321.9K
- Jun 2019Post IPO$16M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Boston is moving
A read on the academic research around Bioinformatics in Boston — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 293 papers.
- Boston University120
- Boston Children\'s Hospital117
- Boston Medical Center21
- Boston Children\'s Museum20
- Boston VA Research Institute18
- Gene3→19
- Transcriptome2→12
- Genome1→7
- Immune system2→8
- CRISPR2→6
- Disease1→8
- DNA sequencing1→3
- Human genetics1→3
- Disease1→4
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.